Corcept Therapeutics (CORT) just delivered a sharp jump in profitability in its third quarter report, with net income of US$126.78 million and diluted EPS of US$1.01 from continuing operations. That profit jump landed against a sharp reset in sentiment, with Corcept Therapeutics’ share price down 40.11% over the past month and 35.33% over 90 days, even after an 87.51% year-to-date share price gain and a 186.18% three-year total shareholder return that points to strong long-run backing for the...
Corcept Therapeutics Inc (CORT) posted $340.5 million in Q3 2026 revenue on explosive oncology growth, reiterated its full-year guidance, and now awaits a December 17 FDA decision on relacorilant.
Motley Fool Press Release.
Corcept (CORT) delivered earnings and revenue surprises of +48.53% and +3.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Apa Corp (APA-Q) from The Globe and Mail including charting and trades.
Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.
Corcept is Tuesday's IBD Stock Of The Day. Shares hit the skids on a medical sell-off, but stayed above the 21-day line.
This is the newest page. Registered accounts read further back.